Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTGIKZ9V)

• DOT Name: Nuclear pore complex-interacting protein family member A5 (NPIPA5)
• Gene Name: NPIPA5
• Related Disease: Pseudoxanthoma elasticum
• UniProt ID: NPIA5_HUMAN
• Pfam ID: PF06409
• Sequence:
  MFCCLGYEWLSGGCKTWHSAWVINTLADHRHRGTDFGGSPWLLIITVFLRSYKFAISLCT
  SYLCVSFLKTIFPSQNGHDGSTDVQQRARRSNCRRQEGIKIVLEDIFTLWRQVETKVRAK
  IRKMKVTTKVNRHDKINGKRKTAKEHLRKLSMKEREHGEKERQVSEAEENGKLDMKEIHT
  YMEMFQRAQALRRRAEDYYRCKITPSARKPLCNRVRMAAVEHRHSSGLPYWPYLTAETLK
  NRMGHQPPPPTQQHSIIDNSLSLKTPSERLLYPLPPSADDNLKTPPECLLTPLPPSALPS
  ADDNLKTPAECLLTPLPPSAPPSADDNLKTPPECVCSLPFHPQRMIISRN

Molecular Interaction Atlas (MIA) of This DOT

1 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Pseudoxanthoma elasticum	DIS8WUQG	Strong	Genetic Variation	[1]

3 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Tretinoin	DM49DUI	Approved	Tretinoin decreases the expression of Nuclear pore complex-interacting protein family member A5 (NPIPA5).	[2]
(+)-JQ1	DM1CZSJ	Phase 1	(+)-JQ1 increases the expression of Nuclear pore complex-interacting protein family member A5 (NPIPA5).	[3]
Mivebresib	DMCPF90	Phase 1	Mivebresib increases the expression of Nuclear pore complex-interacting protein family member A5 (NPIPA5).	[3]

References

• [1] Identification of novel polymorphisms in the pM5 and MRP1 (ABCC1) genes at locus 16p13.1 and exclusion of both genes as responsible for pseudoxanthoma elasticum.Hum Mutat. 2001;17(1):74-5. doi: 10.1002/1098-1004(2001)17:1<74::AID-HUMU14>3.0.CO;2-F.
• [2] Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
• [3] Comprehensive transcriptome profiling of BET inhibitor-treated HepG2 cells. PLoS One. 2022 Apr 29;17(4):e0266966. doi: 10.1371/journal.pone.0266966. eCollection 2022.